Purpose: To assess the effect of a pharmacist-managed collaborative drug therapy agreement (CDTA) on the management of diabetes mellitus (MD) in an outpatient setting. There is a great lack of knowledge and understanding about the role of clinical pharmacists and in the concept of CDTM. This lack of knowledge has impacted collaboration between clinical pharmacists and physicians in different environments. Informing healthcare providers and stakeholders about the role of clinical pharmacists in providing drug therapy management and promoting the CDM concept among healthcare providers are the main solutions to strengthen the role of the clinical pharmacist in patient care. A structured survey was developed following a literature review of the CDTM. The questions were validated to assess awareness of the role of clinical pharmacists in providing drug therapy management and to identify the main obstacles to the lack of cooperation agreements with different disciplines. In addition to demographic data, the education of doctors, the reasons for the withdrawal of clinical pharmacy services in their clinics and their perceptions of the signing of a cooperation agreement were also collected. The sample for the study was obtained from different health specialties in Saudi Arabia. The validated survey was released and received in about two months, Oct-Nov 2017. We received 55 responses from different sectors, a response rate of 79%. Most doctors had previously worked with a clinical pharmacist (76%), of which 60% of the clinical pharmacist`s services are considered extremely important or extremely important. 29.1% and 30.9%.
When doctors asked if they had heard of the collaborative therapy management agreement or the term CDTM, 67% of respondents had never heard of it. Most of the responses regarding physician awareness of CDTM agreement services were correct. Only 18% chose fake CDTM services. The results showed a higher percentage of physicians who agreed with the benefits of the CDM agreement, as they improve overall patient care, reduce the risk of adverse drug-related events or interactions, and allow clinical pharmacists to be part of patient care; 85.5, 83.6 and 83.6. Doctors who considered that the possibility of encouraging other health professionals to sign cooperation agreements was 76.3 and 74.5 respectively. Based on their specialty, emergency medicine physicians were most likely to have a CDM agreement and encourage others. On a scale of zero to one hundred, the average response that considered lack of awareness of such an agreement as a potential obstacle to CDM prevention was 69± 0.30. While the barrier between the sexes was the lowest, with an average of 15..